{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-006887","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2022-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.744907+00:00","generated_at":"2026-06-26T21:01:47.397270+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Absci posts Q4 revenue $1.5M, net loss $25.2M; reveals AI antibody design breakthroughs, partners NVIDIA","bullets":["Q4 2021 revenue $1.5M, net loss $25.2M vs $4.9M YoY; FY2021 net loss $101.0M vs $14.4M.","Cash of $279.9M; expects ~$120M net cash burn in 2022 (incl. ~$10.5M restricted cash).","Announced ML models predicting antibody affinity across 4 orders of magnitude and naturalness scoring.","Formed research collaboration with NVIDIA to scale in-silico drug discovery on A100 GPUs.","Entered Merck collaboration for Bionic Enzyme; projected 8 active programs in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-006887","json":"https://secwatch.observer/filing/0001628280-22-006887.json","markdown":"https://secwatch.observer/filing/0001628280-22-006887.md","text":"https://secwatch.observer/filing/0001628280-22-006887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022006887/0001628280-22-006887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022006887/absc-20220322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:01:47.397270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}